Pathophysiology of Hypertension

Hypertension: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2007, Pages 25-46

  Franco, Veronica ^a   Calhoun, David A ^a   Oparil, Suzanne ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77955367651     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4160-3053-9.50009-3     Document Type: Chapter

References (100)

1. Oparil S, Zaman A, Calhoun DA Pathogenesis of hypertension. Ann Intern Med 2003, 139:761-776.
2. Calhoun DA, Zaman A, Oparil S Etiology and pathogenesis of systemic hypertension. Cardiology 2003, 463-471. Mosby, Philadelphia. 2nd ed. M.H. Crawford, J.P. DiMarco, W.J. Paulus (Eds.).
3. Delgado MC, Weder AB Pathophysiology of hypertension. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 29-38. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).
4. Lifton RP, Gharavi AG, Geller DS Molecular mechanisms of human hypertension. Cell 2001, 104:545-556.
5. Harrap SB Blood pressure genetics. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 39-59. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).
6. Feinleib M, Garrison RJ, Fabsitz R, et al. The NHLBI twin study of cardiovascular disease risk factors: Methodology and summary of results. Am J Epidemiol 1977, 106:284-285.
7. Longini IM, Higgins MW, Hinton PC, et al. Environmental and genetic sources of familial aggregation of blood pressure in Tecumseh, Michigan. Am J Epidemiol 1984, 120:131-144.
8. Biron P, Mongeau JG, Bertrand D Familial aggregation of blood pressure in 558 adopted children. Can Med Assoc J 1976, 115:773-774.
9. Guyton AC Blood pressure control: Special role of the kidneys and body fluids. Science 1991, 252:1813-1816.
10. Matsuo A, Katsuya T, Ishikawa K, et al. G2736A polymorphism of thiazide-sensitive Na-Cl cotransporter gene predisposes to hypertension in young women. J Hypertens 2004, 22:2123-2127.
11. Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: Heritable human hypertension caused by mutations in the β-subunit of the epithelial sodium channel. Cell 1994, 79:407-414.
12. Melander O, Orho M, Fagerudd J, et al. Mutations and variants of the epithelial sodium channel gene in Liddle's syndrome and primary hypertension. Hypertension 1998, 31:1118-1124.
13. Carter AR, Zhou ZH, Calhoun DA, Bubien JK Hyperactive ENaC identifies hypertensive individuals amenable to amiloride therapy. Am J Physiol 2001, 281:413-421.
14. Jeunemaitre X, Soubrier F, Kotelevtsev YV, et al. Molecular basis of human hypertension: Role of angiotensinogen. Cell 1992, 71:169-180.
15. Corvol P, Persu A, Giminez-Roqueplo AP, Jeunemaitre X Seven lessons from two candidate genes in human essential hypertension: Angiotensinogen and epithelial sodium channel. Hypertension 1999, 33:1324-1331.
16. Staessen JA, Kuznetsova T, Wang JG, et al. M235T angiotensinogen gene polymorphism and cardiovascular renal risk. J Hypertens 1999, 17:9-17.
17. Rigat B, Hubert C, Alhenc-Gelas F, et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990, 86:1343-1346.
18. Fornage M, Amos CI, Kardia S, et al. Variation in the region of the angiotensin-converting enzyme gene influences interindividual differences in blood pressure levels in young white males. Circulation 1998, 97:1773-1779.
19. O'Donnell C, Lindpaintner K, Larson MG, et al. Evidence for association and genetic linkage of the angiotensin-converting enzyme locus with hypertension and blood pressure in men but not women: The Framingham Heart Study. Circulation 1998, 97:1766-1772.
20. Spiering W, Kroon AA, Fuss-Lejeune MJ, de Leeuw PW Genetic contribution to the acute effects of angiotensin II type 1 receptor blockade. J Hypertens 2005, 23:753-758.
21. Niu T, Chen X, Xiping X Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease. Drugs 2000, 62:977-993.
22. Bianchi G, Ferrari P, Staessen JA Adducin polymorphism: Detection and impact on hypertension and related disorders. Hypertension 2005, 45:331-340.
23. Turner ST, Schwartz GL Gene markers and antihypertensive therapy. Curr Hypertens Rep 2005, 7:21-30.
24. Manunta P, Cusi D, Barlassina C, et al. Alpha-adducin polymorphisms and renal sodium handling in essential hypertensive patients. Kidney Int 1998, 53:1471-1478.
25. Grant FD, Romero JR, Jeunemaitre X, et al. Low-renin hypertension, altered sodium homeostasis, and α-adducin polymorphism. Hypertension 2002, 39:191-196.
26. Arnett DK, Boerwinkle E, Davis BR, et al. Pharmacogenetic approach to hypertension therapy: Design and rationale for the Genetics of Hypertension Associated Treatment (GenHAT) study. Pharmacogenomics J 2002, 2:309-317.
27. Cusi D, Barlassina C, Azzani T, et al. Polymorphisms of alpha-adducin and salt sensitivity in patients with essential hypertension. Lancet 1997, 349:1353-1357.
28. Turner ST, Chapman AB, Schwartz GL, Boerwinkle E Effects of endothelial nitric oxide synthase, alpha-adducin, and other candidate gene polymorphisms on blood pressure response to hydrochlorothiazide. Am J Hypertens 2003, 16:834-839.
29. Psaty BM, Smith NL, Heckbert SR, et al. Diuretic therapy, the a-adducin gene variant, and the risk of myocardial infarction or stroke in persons with treated hypertension. JAMA 2002, 287:1680-1689.
30. Schwartz GL, Turner ST, Chapman AB, Boerwinkle E Interacting effects of gender and genotype on blood pressure response to hydrochlorothiazide. Kidney Int 2002, 62:1718-1723.
31. Manunta P, Tripodi G Haplotype analysis in human hypertension. J Hypertens 2005, 23:711-712.
32. International Human Genome Sequencing Consortium Finishing the euchromatic sequence of the human genome. Nature 2004, 431:931-945.
33. Persu A, Vinck WJ, Khattabi OE, et al. Influence of the endothelial nitric oxide synthase gene on conventional and ambulatory blood pressure: Sib-pair analysis and haplotype study. J Hypertens 2005, 23:759-765.
34. Yagil C, Hubner N, Monti J, et al. Identification of hypertension-related genes through an integrated genomic-transcriptomic approach. Circ Res 2005, 96:617-625.
35. Winslow RL, Gao Z Candidate gene discovery in cardiovascular disease [editorial]. Circ Res 2005, 96:605-606.
36. Selby JV, Newman B, Quiroga J, et al. Concordance for dyslipidemic hypertension in male twins. JAMA 1991, 265:2079-2084.
37. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998, 339:229-234.
38. Chobanian AV, Bakris GL, Black HR, the National High Blood Pressure Education Program Committee, et al. Seventh report on the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. The JNC 7 Report. Hypertension 2003, 42:1206-1252.
39. Reaven GM, Lithell H, Landsberg L Hypertension and associated metabolic abnormalities: The role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334:374-381.
40. Brook RD, Julius S Autonomic imbalance, hypertension and cardiovascular risk. Am J Hypertens 2000, 13:112S-122S.
41. Kim J-R, Kiefe CI, Liu K, et al. Heart rate and subsequent blood pressure in young adults: The CARDIA Study. Hypertension 1999, 33:640-646.
42. Esler M The sympathetic system and hypertension. Am J Hypertens 2000, 13:99S-105S.
43. Izzo JL The sympathetic nervous system in acute and chronic blood pressure elevation. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 60-76. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).
44. Abboud FM The sympathetic system in hypertension. Hypertension 1982, 4:208-225.
45. Joyner MJ, Shepherd JT, Seals DR Sustained increases in sympathetic outflow during prolonged lower body negative pressure in humans. J Appl Phyisiol 1990, 68:1004-1009.
46. Fink GD, Haywood JR, Bryan WJ, et al. Central site for pressor action of blood-borne angiotensin in rat. Am J Physiol 1980, 239:R358-R361.
47. Allen K, Shykoff BE, Izzo JL Cognitive appraisal of threat or challenge predicts hemodynamic responses to mental arithmetic and speech tasks [abstract]. Am J Hypertens 1998, 11(Suppl 1):134A.
48. Shykoff BE, Allen K, Izzo JL Interactions of social support and family history in blood pressure reactivity to psychological stressors [abstract]. Am J Hypertens 1998, 11(Suppl 1):135A.
49. Oparil S, Chen YF, Berecek K, et al. The role of the central nervous system in hypertension. Hypertension: Pathophysiology, Diagnosis and Management 1995, 713-740. Raven Press, New York. J.H. Laragh, B.M. Brenner (Eds.).
50. Oparil S, Chen YF, Peng N, et al. Anterior hypothalamic norepinephrine, atrial natriuretic peptide and hypertension. Front Neuroendocrinol 1996, 17:211-246.
51. Chapleau MW, Hajduczok G, Abboud FM Mechanisms of resetting of arterial baroreceptors: An overview. Am J Med Sci 1988, 295:327-334.
52. Xie P, Chapleau MW, McDowell TX, et al. Mechanisms of decreased baroreceptor activity in chronic hypertensive rabbits: Role of endogenous prostanoids. J Clin Invest 1990, 86:625-630.
53. Xie P, McDowell TS, Chapleau MW, et al. Rapid baroreceptor resetting in chronic hypertension: Implications for normalization of arterial pressure. Hypertension 1991, 17:72-79.
54. Guo GB, Abboud FM Impaired central mediation of the arterial baroreflex in chronic renal hypertension. Am J Physiol 1984, 15:H720-H727.
55. Guo GB, Abboud FM Angiotensin II attenuates baroreflex control of heart rate and lumbar sympathetic nerve activity. Am J Physiol 1984, 15:H80-H89.
56. Abboud FM Effects of sodium, angiotensin, and steroids on vascular reactivity in man. Fed Proc 1974, 33:143-149.
57. Li Z, Mao HZ, Abboud FM, Chapleau MW Oxygen-derived free radicals contribute to baroreceptor dysfunction in atherosclerotic rabbits. Circ Res 1996, 79:802-811.
58. Chapleau MW, Hajduczok G, Abboud FM Suppression of baroreceptor discharge by endothelin at high carotid sinus pressure. Am J Physiol 1982, 263:R103-R108.
59. Randall OS, Esler MD, Bulloch EG, et al. Relationship of age and blood pressure to baroreflex sensitivity and arterial compliance in man. Clin Sci Mol Med 1976, (Suppl 3):357S-360S.
60. Somers VK, Mark AL, Abboud FM Potentiation of sympathetic nerve responses to hypoxia in borderline hypertensive subjects. Hypertension 1988, 11:608-612.
61. Somers VK, Dyken ME, Clary MP, Abboud FM Sympathetic neural mechanisms in obstructive sleep apnea. J Clin Invest 1995, 96:1897-1904.
62. Esler M, Jennings G, Lambert G, et al. Overflow of catecholamine neurotransmitters to the circulation: Source, fate, and functions. Physiol Rev 1990, 70:963-985.
63. Hollenberg NK, Adams DF, Solomon H, et al. Renal vascular tone in essential and secondary hypertension: Hemodynamic and angiographic responses to vasodilators. Medicine (Baltimore) 1975, 54:29-44.
64. DiBona GF, Kopp UC Neural control of renal function: Role in human hypertension. Hypertension: Pathophysiology, Diagnosis, and Management 1995, 1349-1358. Raven Press, New York. 2nd ed. J.H. Laragh, B.M. Brenner (Eds.).
65. Thoren P, Ricksten S-E Recordings of renal and splanchnic sympathetic nervous activity in normotensive and spontaneously hypertensive rats. Clin Sci 1979, 57(Suppl 5):197S-199S.
66. Converse RL, Acobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med 1992, 327:1912-1918.
67. Frohlich ED Other adrenergic inhibitors and the direct-acting smooth muscle vasodilators. Hypertension. A Companion to Brenner and Rector's The Kidney 2000, 637-643. WB Saunders, Philadelphia. S. Oparil, M.A. Weber (Eds.).
68. Light KC Environmental and psychosocial stress in hypertension onset and progression. Hypertension. A Companion to Brenner and Rector's The Kidney 2000, 59-70. WB Saunders, Philadelphia. S. Oparil, M.A. Weber (Eds.).
69. Calhoun DA, Mutinga ML, Collins AS, et al. Normotensive blacks have heightened sympathetic response to cold pressor test. Hypertension 1993, 22:801-805.
70. Folkow B Physiological aspects of primary hypertension. Physiol Rev 1982, 62:347-504.
71. Schiffrin EL Effects of antihypertensive drugs on vascular remodeling: Do they predict outcome in response to antihypertensive therapy?. Curr Opin Nephrol Hypertens 2001, 10:617-624.
72. Mendelsohn ME In hypertension, the kidney is not always the heart of the matter. J Clin Invest 2005, 115:840-844.
73. Hirooka Y, Shimokawa H, Takeshita A Rho-kinase, a potential therapeutic target for the treatment of hypertension. Drug News Perspect 2004, 17:523-527.
74. Crowley SD, Gurley SB, Oliverio MI, et al. Distinct roles for the kidney and systemic tissues in blood pressure regulation by the renin-angiotensin system. J Clin Invest 2005, 115:1092-1099.
75. Johnson RJ, Rodriguez-Iturbe B, Kang D-H, et al. A unifying pathway for essential hypertension. Am J Hypertens 2005, 18:431-440.
76. Culleton BF, Larson MG, Kannel WB, Levy D Serum uric acid and risk for cardiovascular disease and death: The Framingham Study. Ann Intern Med 1999, 131:7-13.
77. Messerli FH, Frohlich ED, Dreslinski GR, et al. Serum uric acid in essential hypertension: An indicator of renal vascular involvement. Ann Intern Med 1980, 93:817-821.
78. Franse LV, Pahor M, Di Bari M, et al. Serum uric acid, diuretic treatment and risk of cardiovascular events in the Systolic Hypertension in the Elderly Program. J Hypertens 2000, 18:1149-1154.
79. Hoieggen A, Alderman MA, Kjeldsen SE, for the LIFE Study Group, et al. The impact of serum uric acid on cardiovascular outcomes in the LIFE study. Kidney Int 2004, 65:1014-1019.
80. Mazzali M, Kanellis J, Han L, et al. Hyperuricemia induces a primary renal arteriolopathy in rats by a blood pressure-independent mechanism. Am J Physiol Renal Physiol 2002, 282:F991-F997.
81. Rao GN, Corson MA, Berk BC Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet derived growth factor A-chain expression. J Biol Chem 1991, 266:8604-8608.
82. Reudelhuber TL Renin. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 89-94. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).
83. Alderman MH, Madhavan S, Ooi WL, et al. Association of the renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 1991, 324:1098-1104.
84. Tipnis SR, Hooper NM, Hyde R, et al. A human homolog of angiotensin-converting enzyme: Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000, 277:33238-33243.
85. Tea BS, Der Sarkissian S, Touyz RM, et al. Proapoptotic and growth-inhibitory role of angiotensin II type 2 receptor in vascular smooth muscle cells of spontaneously hypertensive rats in vivo. Hypertension 2000, 35:1069-1073.
86. Carey RM, Siragy HM Newly recognized components of the renin-angiotensin system: Potential roles in cardiovascular and renal regulation. Endocr Rev 2003, 24:261-271.
87. Fukui T, Ishizaka N, Rajagopalan S, et al. p22phox mRNA expression and NADPH oxidase activity are increased in aortas from hypertensive rats. Circ Res 1997, 80:45-51.
88. Funder JW Aldosterone and mineralocorticoids. Hypertension. A Companion to Brenner & Rector's The Kidney 2005, 117-122. Elsevier, Philadelphia. 2nd ed. S. Oparil, M.A. Weber (Eds.).
89. Mihailidou A, Mardini M, Funder JW Rapid, nongenomic effects of aldosterone in the heart mediated by epsilon protein kinase C. Endocrinology 2004, 145:773-780.
90. Fardella CE, Mosso L, Gomez-Sanchez C, et al. Primary hyperaldosteronism in essential hypertensives: Prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab 2000, 85:1863-1867.
91. Goodfriend TL, Calhoun DA Resistant hypertension, obesity, sleep apnea, and aldosterone: Theory and therapy. Hypertension 2004, 43:518-524.
92. Nishizaka MK, Zaman MA, Calhoun DA Efficacy of low-dose spironolactone in subjects with resistant hypertension. Am J Hypertens 2003, 16:925-930.
93. Nishizaka MK, Zaman MA, Green SA, et al. Impaired endothelium-dependent flow-mediated vasodilation in hypertensive subjects with hyperaldosteronism. Circulation 2004, 109:2857-2861.
94. Ibsen H, Olsen MH, Wachtell K, et al. Reduction in albuminuria translates to reduction in cardiovascular events in hypertensive patients: Losartan Intervention For Endpoint Reduction in Hypertension study. Hypertension 2005, 45:198-202.
95. Krum H, Viskoper RJ, Lacouciere Y, et al. The effect of an endothelin-receptor antagonist, bosentan, on blood pressure in patients with essential hypertension: Bosentan Hypertension Investigators. N Engl J Med 1998, 338:784-790.
96. Campese VM, Nadim MK Natriuretic peptides. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 169-192. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).
97. Wang D, Oparil S, Feng JA, et al. Effects of pressure overload on extracellular matrix expression in the heart of the atrial natriuretic peptide-null mouse. Hypertension 2003, 42:88-95.
98. Takimoto E, Champion HC, Li M, et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005, 11:214-222.
99. Carretero O, Yang XP, Rhaleb NE The kallikrein-kinin system as a regulator of cardiovascular and renal function. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 203-218. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).
100. Watson RE, DiPette DJ, Supowit SC, et al. Vasodilator peptides: CGRP, substance P, and adrenomedullin. Hypertension, 2nd ed. A Companion to Brenner & Rector's The Kidney 2005, 193-202. Elsevier, Philadelphia. S. Oparil, M.A. Weber (Eds.).